Research location
Verona
VR, Italy
Advertisement
Research activity in Verona
VR, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 42 trials and 42 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Verona
41 linked trials · page 1 of 1A Study of F8IL10 Intra-articular Treatment in Rheumatoid ArthritisNCT07245992 · 2026-03-04 · 1 site observation
RECRUITING
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT07190300 · 2026-01-13 · 1 site observation
RECRUITING
Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLCNCT07356544 · 2025-08-12 · 1 site observation
RECRUITING
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaNCT06597019 · 2024-12-09 · 1 site observation
RECRUITING
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT06991556 · 2025-07-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanced PCaNCT07352748 · 2024-10-17 · 1 site observation
ACTIVE_NOT_RECRUITING
All-in-One Prostate Cancer Staging with MRINCT06071195 · 2021-12-22 · 1 site observation
UNKNOWN
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)NCT05147220 · 2021-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic SurgeryNCT04615091 · 2020-08-30 · 1 site observation
UNKNOWN
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to OfatumumabNCT04353492 · 2020-07-14 · 1 site observation
COMPLETED
Efficacy of Nuts in Obese Children.NCT03870984 · 2019-03-19 · 1 site observation
TERMINATED
A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaNCT02974725 · 2017-02-24 · 1 site observation
TERMINATED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabNCT02926196 · 2016-06-17 · 1 site observation
COMPLETED
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.NCT02563067 · 2015-12-03 · 1 site observation
COMPLETED
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationNCT02468661 · 2015-09-23 · 1 site observation
TERMINATED
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)NCT02414139 · 2015-06-11 · 1 site observation
COMPLETED
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)NCT02299505 · 2015-04-09 · 1 site observation
COMPLETED
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to LeptomeningesNCT02336451 · 2015-04-01 · 1 site observation
COMPLETED
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · 2015-02-24 · 1 site observation
COMPLETED
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsNCT02077933 · 2014-05-14 · 1 site observation
COMPLETED
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201NCT02075008 · 2014-03-27 · 1 site observation
TERMINATED
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) PatientsNCT02064868 · 2014-01-31 · 1 site observation
TERMINATED
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibNCT01828112 · 2013-06-28 · 1 site observation
COMPLETED
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With AsthmaNCT01716754 · 2012-12-01 · 1 site observation
COMPLETED
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiNCT01633060 · 2012-10-03 · 1 site observation
TERMINATED
Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.NCT01770379 · 2012-10-01 · 1 site observation
TERMINATED
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of FormoterolNCT01555099 · 2012-04-01 · 1 site observation
COMPLETED
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)NCT01524783 · 2012-03-30 · 1 site observation
COMPLETED
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)NCT01555138 · 2012-02-01 · 1 site observation
COMPLETED
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsNCT01482156 · 2012-01-01 · 1 site observation
COMPLETED
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα AgentsNCT01377012 · 2011-08-30 · 1 site observation
COMPLETED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic SyndromeNCT01181830 · 2010-02-01 · 1 site observation
COMPLETED
Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate AsthmaNCT00849095 · 2009-04-01 · 1 site observation
COMPLETED
Exacerbation StudyNCT00845728 · 2009-03-01 · 1 site observation
COMPLETED
Tarceva Italian Lung Optimization tRialNCT00637910 · 2007-11-01 · 1 site observation
UNKNOWN
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)NCT00549757 · 2007-10-01 · 1 site observation
TERMINATED
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux AsthmaNCT00317044 · 2006-04-01 · 1 site observation
COMPLETED
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast CancerNCT00248170 · 2005-12-01 · 1 site observation
COMPLETED
GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHFNCT00336336 · 2002-08-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.